Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA TrialJosep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.
Gynecologic Oncology|September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trialMansoor R Mirza, B Benigno, A Dørum, et al.
International Journal of Cancer|August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancerIsabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.
Cancer|April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialMansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
Cancer Research Communications|November 26, 2024
Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian CancerMaj K Kjeldsen, Morten Jørgensen, Dina Sofie B Grønseth, et al.
The Lancet. Oncology|November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trialAndreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
The Lancet. Oncology|June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trialAmit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.
The New England Journal of Medicine|December 30, 2011
A phase 3 trial of bevacizumab in ovarian cancerTimothy J Perren, Ann Marie Swart, Jacobus Pfisterer, et al.
BMC Medical Ethics|October 23, 2016
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 studyDavid J Pulford, Philipp Harter, Anne Floquet, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2022
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trialAntonio González-Martín, Christophe Desauw, Florian Heitz, et al.
Pageof 5